Immunome's CEO Dr. Clay Siegall reveals the 3 things that make it exciting to work at Immunome. #patientimpact #defeatcancer #teamimmunome
Immunome, Inc.
Biotechnology Research
Bothell, Washington 10,465 followers
Transformative Targeted Therapies
About us
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.
- Website
-
https://www.immunome.com/
External link for Immunome, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Bothell, Washington
- Type
- Public Company
- Specialties
- Biotechnology
Locations
-
Primary
Get directions
18702 North Creek Pkwy
100
Bothell, Washington 98011, US
Employees at Immunome, Inc.
Updates
-
Immunome Reported Third Quarter 2025 Financial Results and Provided a Business Update: “Immunome’s pipeline continues to advance,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “We anticipate the release of topline data for the RINGSIDE trial of varegacestat before the end of this year, to be followed by an NDA submission if warranted.” Read the press release: https://lnkd.in/g3KGmB4K
-
Our Chief Business Officer Kinney Horn talks about why he's excited about the future of Immunome as our team presents at the Triple Meeting in Boston.
-
Immunome recently presented preclinical data showing its proprietary antibody-drug conjugate (ADC) payload HC74 overcomes multiple mechanisms of ADC resistance, including payload efflux and target heterogeneity. HC74 is a novel topoisomerase I inhibitor that serves as the payload in IM-1021, a ROR1-targeted ADC currently in a Phase 1 trial for solid and liquid tumors, and as the payload in several preclinical candidates within the Immunome pipeline. Read the full release here: https://lnkd.in/gmXP-RuN
-
🚀 Exciting news from Infinimmune! Today, we announced a research collaboration with Immunome, Inc. (NASDAQ: IMNM) to discover and optimize novel antibodies. Under the agreement, Immunome, Inc. will receive target exclusivity, while Infinimmune will apply our GLIMPSE™ and Anthrobody® platforms to rapidly advance high-fidelity, human-first therapeutic candidates. “Infinimmune expects this collaboration to demonstrate how our GLIMPSE™ platform can optimize and enhance existing antibodies with unprecedented speed,” said Wyatt McDonnell, CEO & Co-Founder, Infinimmune. “As GLIMPSE was trained on our proprietary human antibody data, we’re able to systematically improve key properties like affinity, stability, and developability while maintaining the human-like characteristics that are critical for therapeutic success.” We’re excited to partner with Immunome in bringing forward the next generation of antibody therapeutics. 🔗https://lnkd.in/egA-ZkXS #AntibodyEngineering #Biotech #GLIMPSE #Anthrobody #Immunome #Infinimmune
-
-
Why work at immunome? Cutting edge science and smart people! https://lnkd.in/gxph7zCY
Why work here? Cutting Edge Science and smart people
https://vimeo.com/
-
Immunome announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC. “Immunome is developing differentiated ADCs that we believe can greatly benefit cancer patients,” said Bob Lechleider, M.D., Chief Medical Officer at Immunome. “The dosing of our first patient with IM-1021 advances that mission, as we work to establish safety and explore efficacy of IM-1021 in patients with high unmet need in B-cell lymphomas and solid tumors.” IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome’s proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1021. The study is expected to include participants with advanced B-cell lymphomas and advanced solid tumors. https://lnkd.in/ekrRhNNb
-
Desmoid tumors can have a dramatic impact on patients. Immunome is evaluating varegacestat (formerly AL102) as an oral, once-daily gamma secretase inhibitor (GSI) therapy for the treatment of Desmoid tumors. Enrollment in RINGSIDE, a Phase 3 registrational trial comparing varegacestat with placebo for the treatment of progressing desmoid tumors, was completed in February 2024, and we expect to report topline data from this trial in the second half of 2025.
📣 At the DTRF, we want to “Spread the Word” far and wide that desmoid tumors are NOT benign. The medical community, research publications, and other sources often use differing terms when describing desmoid tumors. Over the years, we’ve heard countless stories that this is confusing to patients as well as clinicians. This confusion can lead to misunderstandings about treatment and minimizes the potentially serious consequences of this rare disease. 💡 Desmoid tumors (also known as aggressive fibromatosis, desmoid fibromatosis, and desmoid-type fibromatosis) do not metastasize. They are classified by the World Health Organization (WHO) as “Intermediate (locally aggressive)” soft tissue tumors. They do not fall under “Benign” or “Malignant” classifications. 🔗 Learn more about desmoid tumors’ classification and much more by visiting our website: https://lnkd.in/e7X-Wb4h 🎉 In honor of Rare Disease Day on February 28th, you’ll see a variety of awareness and educational content over the next couple of months to help correct this common misconception. To make a significant impact on behalf of the patient community, we invite you to like, share, and spread the word that desmoid tumors are NOT benign. #DesmoidsareNOTbenign #SpreadtheWord #DTRF #DesmoidTumorResearchFoundation #desmoid #desmoidtumor #desmoidawareness #aggressivefibromatosis #Desmoidian #desmoidresearch #FAP #familialadenomatouspolyposis #OrphanDisease #raredisease #sarcoma #sarcomaawareness #oncology #hope
-
-
Immunome will participate in the following investor conferences in March 2025: TD Cowen 45th Annual Health Care Conference Conference Dates: March 3-5, 2025 Presentation Date/Time: March 4, 2025, 1:10 p.m. ET Leerink Partners Global Healthcare Conference 2025 Conference Dates: March 10-12, 2025 Presentation Date/Time: March 10, 2025, 1:40 p.m. ET Live webcast links for both presentations will be available on the events tab of Immunome’s investor website: https://lnkd.in/ghrW_aMh Replay links of the presentations will also be available on the website for 30 days following the live broadcast.